Medpace Holdings, Inc. (FRA:01P)

Germany · Delayed Price · Currency is EUR

383.90

+5.50 (1.45%)

At close: Feb 20, 2026

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Oncology Revenue	747.59M	651.24M
Oncology Revenue Growth	14.79%	10.93%
Metabolic Revenue	744.96M	457.54M
Metabolic Revenue Growth	62.82%	21.41%
Other Sources of Revenue	408.55M	431.38M
Other Sources of Revenue Growth	-5.29%	6.56%
Cardiology Revenue	239.37M	230.45M
Cardiology Revenue Growth	3.87%	18.98%
Central Nervous System Revenue	254.84M	181.98M
Central Nervous System Revenue Growth	40.04%	13.69%
AVAI Revenue	134.94M	156.46M
AVAI Revenue Growth	-13.76%	-4.20%
Revenue (Total)	2.53B	2.11B
Revenue (Total) Growth	19.97%	11.84%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Net New Business Awards	2.65B	2.23B
Net New Business Awards Growth	18.69%	-5.38%
Total Backlog	3.03B	2.90B
Total Backlog Growth	4.31%	3.17%
Book-to-Bill Ratio	1.05	1.06
Book-to-Bill Ratio Growth	-0.94%	-15.20%

Updated Dec 31, 2025. Data Source: Fiscal.ai.